Search - tctmd.com

Displaying 281 - 300 of 596

Sort: Relevancy | Date

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

News Daily News

研究结果支持ACS患者的DAPT治疗持续3个月以上

L.A. McKeown

November 01, 2013

News Daily News

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

L.A. McKeown

November 01, 2013

News Daily News

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

L.A. McKeown

November 01, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Industry News

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Industry News

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

October 29, 2013

News Conference News TCT 2013

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

October 29, 2013

Advertisement

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

研究结果支持ACS患者的DAPT治疗持续3个月以上

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

OPTIMIZE: 3-Month DAPT Safe with ZES

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Innovation in Intervention: Perspectives from Industry

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content